1. Search Result
Search Result
Results for "

Biliary

" in MedChemExpress (MCE) Product Catalog:

60

Inhibitors & Agonists

1

Fluorescent Dye

1

Peptides

2

Inhibitory Antibodies

16

Natural
Products

3

Recombinant Proteins

6

Isotope-Labeled Compounds

2

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-119412

    Reactive Oxygen Species (ROS) Metabolic Disease
    Biliatresone is a natural toxin isolated from Dysphania glomulifera and D. littoralis. Biliatresone, a 1,2-diaryl-2-propenone class of isoflavonoid, produces extrahepatic biliary atresia in a zebrafish model .
    Biliatresone
  • HY-W018512
    7-Ketolithocholic acid
    4 Publications Verification

    3α-Hydroxy-7-oxo-5β-cholanic acid

    Endogenous Metabolite Metabolic Disease
    7-Ketolithocholic acid (3α-Hydroxy-7-oxo-5β-cholanic acid), a bile acid, can be absorbed and suppresses endogenous bile acid production and biliary cholesterol secretion .
    7-Ketolithocholic acid
  • HY-109120
    Odevixibat
    3 Publications Verification

    A4250

    Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
    Odevixibat
  • HY-B0998

    Dehydrocholate sodium

    Amylases Lipase Autophagy Metabolic Disease
    Dehydrocholic acid (Dehydrocholate) sodium is an orally active hydrocholeretic agent. Dehydrocholic acid sodium modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid sodium has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid sodium can be used in the study of acute biliary pancreatitis and obstructive jaundice .
    Dehydrocholic acid sodium
  • HY-B1393

    Dehydrocholate

    Autophagy Amylases Lipase Metabolic Disease
    Dehydrocholic acid (Dehydrocholate) is an orally active hydrocholeretic agent. Dehydrocholic acid modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid can be used in the study of acute biliary pancreatitis and obstructive jaundice .
    Dehydrocholic acid
  • HY-105047

    NRL972

    Biochemical Assay Reagents Metabolic Disease
    Fluorescein lisicol is a fluorescent-labelled bile salt and a marker of hepatic biliary transporter function. Fluorescein lisicol can be used for metabolic research .
    Fluorescein lisicol
  • HY-201296A

    TUCA sodium

    Drug Isomer Cancer
    Tauroursocholic acid (TUCA) sodium is a taurine-conjugated form of the bile acid ursocholic acid and the 7β-hydroxy epimer of Taurocholic acid (HY-B1788). Tauroursocholic acid sodium exists in abundance during the biliary tract cancer, disrupting the balance and cellular toxicity of bile acids and inducing carcinogenesis through oxidative DNA damage and DNA mutation. Tauroursocholic acid (TUCA) sodium can be used for biliary tract cancer research .
    Tauroursocholic acid sodium
  • HY-W018512R

    3α-Hydroxy-7-oxo-5β-cholanic acid (Standard)

    Reference Standards Endogenous Metabolite Metabolic Disease
    7-Ketolithocholic acid (Standard) is the analytical standard of 7-Ketolithocholic acid. This product is intended for research and analytical applications. 7-Ketolithocholic acid (3α-Hydroxy-7-oxo-5β-cholanic acid), a bile acid, can be absorbed and suppresses endogenous bile acid production and biliary cholesterol secretion .
    7-Ketolithocholic acid (Standard)
  • HY-E70413

    Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    Amino acid arylamidase, hog kidney is a metalloprotease that can hydrolyze proteins or peptides containing free α-amino or α-imino groups, playing a crucial role in amino acid metabolism and protein digestion. Its hydrolytic activity can be blocked by acetylation of the N-terminus. Amino acid arylamidase, hog kidney can be used in research on hepatic diseases, biliary diseases, and heart failure .
    Amino acid arylamidase, hog kidney
  • HY-P991352

    PD-1/PD-L1 Cancer
    SG-001 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. SG-001 can be used in Cervical cancer, Colorectal cancer, Solid tumours and Biliary cancer research .
    SG-001
  • HY-109120S

    A4250-d5

    Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds Metabolic Disease
    Odevixibat-d5 is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
    Odevixibat-d5
  • HY-109120R

    Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    Odevixibat (Standard) is the analytical standard of Odevixibat. This product is intended for research and analytical applications. Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
    Odevixibat (Standard)
  • HY-109120S1

    A4250-13C6

    Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds Metabolic Disease
    Odevixibat- 13C6 is 13C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
    Odevixibat-13C6
  • HY-B1210

    Bacterial Antibiotic Infection
    Pipemidic acid , a derivative of Piromidic acid, is an antibacterial agent. Pipemidic acid inhibits DNA gyrase. Pipemidic acid is active against gram-negative bacteria including Pseudomonas aeruginosa as well as some gram-positive bacteria. Pipemidic acid can be used for the research of intestinal, urinary, and biliary tract infections .
    Pipemidic acid
  • HY-P991554

    TNF Receptor Inflammation/Immunology
    FFP-104 is a humanized IgG4 monoclonal antibody inhibitor targeting TNFRSF5/CD40. VX70 can be used for chronic autoimmune liver diseases research, such as primary biliary cholangitis (PBC) .
    FFP-104
  • HY-16643
    Linerixibat
    10+ Cited Publications

    GSK2330672

    Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease Inflammation/Immunology
    Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC50 of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment .
    Linerixibat
  • HY-B1210R

    Reference Standards Bacterial Antibiotic Infection
    Pipemidic acid (Standard) is the analytical standard of Pipemidic acid. This product is intended for research and analytical applications. Pipemidic acid , a derivative of Piromidic acid, is an antibacterial agent. Pipemidic acid inhibits DNA gyrase. Pipemidic acid is active against gram-negative bacteria including Pseudomonas aeruginosa as well as some gram-positive bacteria. Pipemidic acid can be used for the research of intestinal, urinary, and biliary tract infections .
    Pipemidic acid (Standard)
  • HY-W013766

    Bacterial Antibiotic Infection
    Pipemidic acid trihydrate, a derivative of Piromidic acid, is an antibacterial agent. Pipemidic acid trihydrate inhibits DNA gyrase. Pipemidic acid trihydrate is active against gram-negative bacteria including Pseudomonas aeruginosa as well as some gram-positive bacteria. Pipemidic acid trihydrate can be used for the research of intestinal, urinary, and biliary tract infections .
    Pipemidic acid trihydrate
  • HY-W013766R

    Reference Standards Bacterial Antibiotic Infection
    Pipemidic acid (trihydrate) (Standard) is the analytical standard of Pipemidic acid (trihydrate). This product is intended for research and analytical applications. Pipemidic acid trihydrate, a derivative of Piromidic acid, is an antibacterial agent. Pipemidic acid trihydrate inhibits DNA gyrase. Pipemidic acid trihydrate is active against gram-negative bacteria including Pseudomonas aeruginosa as well as some gram-positive bacteria. Pipemidic acid trihydrate can be used for the research of intestinal, urinary, and biliary tract infections .
    Pipemidic acid trihydrate (Standard)
  • HY-B2119

    Tauroglycocholic acid sodium salt

    Biochemical Assay Reagents Endocrinology
    Sodium tauroglycocholate is an inhibitor of the biliary acid transporting system of the hepatocyte and also a surfactant used as a chemical permeation enhancer.
    Sodium tauroglycocholate
  • HY-106537

    Probilin; Secrebil; Piprozolin

    Others Metabolic Disease
    W 3699 (Probilin; Secrebil; Piprozolin) is a choleretic agent that can be used in the study of biliary diseases .
    W 3699
  • HY-114360
    Taurohyodeoxycholic acid
    2 Publications Verification

    Endogenous Metabolite COX Interleukin Related Glutathione Peroxidase TNF Receptor Metabolic Disease Inflammation/Immunology
    Taurohyodeoxycholic acid is an orally active 6 alpha-hydroxylated bile acid. Taurohyodeoxycholic acid decreases colonic MPO activity, TNF-α, lL-6 serum levels and the expression of COX-2. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance. Taurohyodeoxycholic acid ameliorates high-fat diet-induced nonalcoholic fatty liver disease in mice. Taurohyodeoxycholic acid prevents Taurochenodeoxycholic acid (HY-N2027)-induced hepatotoxicity in bile fistula rats. Taurohyodeoxycholic acid can be used for the study of nonalcoholic fatty liver disease (NAFLD), colitis and biliary fistula .
    Taurohyodeoxycholic acid
  • HY-134988

    FXR Phosphatase Cytochrome P450 Inflammation/Immunology
    EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .
    EDP-305
  • HY-122326

    Ioglycamide

    Biochemical Assay Reagents Metabolic Disease
    Ioglycamic acid (Ioglycamide) is an iodinated biliary contrast agent. Ioglycamic acid reduces bile acid independent cholesterol secretion .
    Ioglycamic acid
  • HY-154857

    Scavenger Receptor Class B type I (SR-BI) Cancer
    1-Palmitoyl-2-succinyl-sn-glycerophosphorylcholine is a glycerophosphorylcholine, consisting of glycerol phosphate, choline and palmitic acid. It accumulates in vivo at sites of oxidative stress. 1-Palmitoyl-2-succinyl-sn-glycerophosphorylcholine may be a ligand of scavenger receptors class B, while oxidized phospholipids oxPC(CD36) are potent ligands of scavenger receptors class B (CD36 and SR-BI). Oxidized phospholipids (oxPLs) also play an important role in tumor apoptosis, may be elevated in malignant biliary strictures .
    1-Palmitoyl-2-succinyl-sn-glycerophosphorylcholine
  • HY-160719

    Peptide-Drug Conjugates (PDCs) Inflammation/Immunology
    NHS-activated 2-octynoic acid-BSA is an immunogen used to establish a murine model of primary biliary cholangitis (PBC). NHS-activated 2-octynoic acid-BSA works in conjunction with Complete Freund's Adjuvant (HY-153808) to stimulate the body's immune system, causing the immune system to recognize it as a foreign antigen and trigger an immune response against autologous biliary epithelial cells. This leads to the production of anti-PDC-E2 antibodies, resulting in bile duct damage and inflammation. NHS-activated 2-octynoic acid-BSA is promising for research of primary biliary cholangitis .
    NHS-activated 2-octynoic acid-BSA
  • HY-B1043

    Bacterial Antibiotic Infection
    Piromidic acid is an antibacterial agent. Piromidic acid is active against gramnegative bacteria and staphylococci and can be used for the research of intestinal, urinary, and biliary tract infections .
    Piromidic acid
  • HY-N15829

    Fluorescent Dye Metabolic Disease
    Cholyl-Lys-fluorescein sodium is a fluorescein-labeled bile acid analog. Cholyl-Lys-fluorescein sodium can be used for biliary atresia validation and for determining in vivo liver function .
    Cholyl-Lys-fluorescein sodium
  • HY-N9516A

    Endogenous Metabolite Metabolic Disease
    Taurodehydrocholic acid sodium is a biliary cholesterol secretion activator. Taurodehydrocholic acid sodium significantly increases the expression of Abcg5 and decreases the expression of abc8. Taurodehydrocholic acid sodium can be used in the study of cholesterol metabolism .
    Taurodehydrocholic acid sodium
  • HY-N9516

    TDHC

    Endogenous Metabolite Metabolic Disease
    Taurodehydrocholic acid is a biliary cholesterol secretion activator. Taurodehydrocholic acid significantly increases the expression of Abcg5 and decreases the expression of abc8. Taurodehydrocholic acid can be used in the study of cholesterol metabolism .
    Taurodehydrocholic acid
  • HY-16737
    Elafibranor
    10+ Cited Publications

    GFT505

    PPAR Metabolic Disease Inflammation/Immunology
    Elafibranor (GFT505) is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively. Elafibranor can be used for the study of primary biliary cholangitis .
    Elafibranor
  • HY-N0545
    Taurocholic acid sodium
    Maximum Cited Publications
    26 Publications Verification

    Sodium taurocholate; N-Choloyltaurine sodium

    VEGFR Endogenous Metabolite Inflammation/Immunology
    Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .
    Taurocholic acid sodium
  • HY-B1788
    Taurocholic acid
    Maximum Cited Publications
    26 Publications Verification

    N-Choloyltaurine

    Endogenous Metabolite Inflammation/Immunology
    Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .
    Taurocholic acid
  • HY-118534

    BRN-2209058

    Endogenous Metabolite Endocrinology
    Cyclobutyrol is a potent choleretic agent. Cyclobutyrol also inhibits biliary lipid secretion. Cyclobutyrol induces choleretic is unrelated to bile acids. Cyclobutyrol and bile acids do not compete for the hepatobiliar transport mechanisms[1]
    Cyclobutyrol
  • HY-118534A

    BRN-2209058 sodium

    Endogenous Metabolite Endocrinology
    Cyclobutyrol sodium is a potent choleretic agent. Cyclobutyrol sodium also inhibits biliary lipid secretion. Cyclobutyrol sodium induces choleretic is unrelated to bile acids. Cyclobutyrol sodium and bile acids do not compete for the hepatobiliar transport mechanisms[1]
    Cyclobutyrol sodium
  • HY-B1043R

    Reference Standards Bacterial Antibiotic Infection
    Piromidic acid (Standard) is the analytical standard of Piromidic acid. This product is intended for research and analytical applications. Piromidic acid is an antibacterial agent. Piromidic acid is active against gramnegative bacteria and staphylococci and can be used for the research of intestinal, urinary, and biliary tract infections .
    Piromidic acid (Standard)
  • HY-113086

    16:1(9Z) CE; 16:1(9Z) Cholesterol ester; Cholesterol Palmitoleate

    Endogenous Metabolite Cardiovascular Disease
    Cholesteryl palmitoleate is a cholesterol ester. Plasma levels of cholesteryl palmitoleate are increased in ApoE-/- mice exposed to cigarette smoke and in pediatric patients with biliary atresia. Cholesteryl palmitoleate has been used as a standard for the identification of cholesterol esters in human meibomian gland secretions.
    CE(16:1(9Z))
  • HY-176510

    PPAR Drug Metabolite Metabolic Disease Inflammation/Immunology
    Elafibranor (GFT505) sulfoxide is a sulfoxide metabolite of Elafibranor (HY-16737). Elafibranor is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively. Elafibranor can be used for the study of primary biliary cholangitis .
    Elafibranor sulfoxide
  • HY-16747

    SHP625 chloride; LUM001 chloride; Lopixibat chloride

    Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia .
    Maralixibat chloride
  • HY-A0140

    Phosphodiesterase (PDE) Neurological Disease
    Drotaverine is a selective phosphodiesterase 4 inhibitor with angina relief activity. Drotaverine is used to suppress angina, including pain in the gastrointestinal tract and biliary tract. Drotaverine may also cause compound-induced priapism, a side effect of sustained penile erection .
    Drotaverine
  • HY-W653893

    Isotope-Labeled Compounds VEGFR Endogenous Metabolite Inflammation/Immunology
    Taurocholic acid-d5 (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .
    Taurocholic acid-d5 sodium
  • HY-W653842

    Sodium taurocholate-d8 (Standard); N-Choloyltaurine-d8 sodium

    Isotope-Labeled Compounds VEGFR Endogenous Metabolite Inflammation/Immunology
    Taurocholic acid-d8 (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .
    Taurocholic acid-d8 sodium
  • HY-16737R

    PPAR Metabolic Disease Inflammation/Immunology
    Elafibranor (Standard) is the analytical standard of Elafibranor. This product is intended for research and analytical applications. Elafibranor (GFT505) is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively. Elafibranor can be used for the study of primary biliary cholangitis .
    Elafibranor (Standard)
  • HY-176347S

    Isotope-Labeled Compounds Cancer
    Alpha Feto Protein, Arg- 13C36, 15N4, Lys- 13C6, 15N2 is the 13C- and 15N-labeled Alpha Feto Protein.
    Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2
  • HY-N0545R

    Sodium taurocholate (Standard); N-Choloyltaurine sodium (Standard)

    Reference Standards VEGFR Endogenous Metabolite Inflammation/Immunology
    Taurocholic acid (sodium) (Standard) is the analytical standard of Taurocholic acid (sodium). This product is intended for research and analytical applications. Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .
    Taurocholic acid sodium (Standard)
  • HY-B1788R

    Taurocholic Acid (Standard)

    Reference Standards Endogenous Metabolite Inflammation/Immunology
    Taurocholic acid (Standard) is the analytical standard of Taurocholic acid. This product is intended for research and analytical applications. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .
    Taurocholic acid (Standard)
  • HY-133707
    β-Muricholic acid
    1 Publications Verification

    Endogenous Metabolite Metabolic Disease
    β-Muricholic acid is a potent and orally active biliary cholesterol-desaturating agent. β-Muricholic acid prevents cholesterol gallstones. β-Muricholic acid inhibits lipid accumulation. β-Muricholic acid has the potential for the research of nonalcoholic fatty liver disease (NAFLD) .
    β-Muricholic acid
  • HY-B1788S2

    Taurocholic Acid-d5

    Isotope-Labeled Compounds Endogenous Metabolite Inflammation/Immunology
    Taurocholic acid-d5 (Taurocholic Acid-d5) is deuterium labeled Taurocholic acid. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .
    Taurocholic acid-d5
  • HY-19522A

    MBX-8025 sodium salt; RWJ-800025 sodium salt

    PPAR Metabolic Disease Inflammation/Immunology
    Seladelpar (MBX-8025) sodium salt is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar sodium salt shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar sodium salt hydrochloride can be used for the study of primary biliary cholangitis .
    Seladelpar sodium salt
  • HY-19522

    MBX-8025; RWJ-800025

    PPAR Metabolic Disease
    Seladelpar (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis .
    Seladelpar

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: